Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeutics, Inc. - Common Stock
(NQ:
ALDX
)
2.160
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aldeyra Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
January 04, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
December 19, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in
Via
Benzinga
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
December 19, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
December 18, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
3 Stocks at the Forefront of Personalized Medicine Trend
December 05, 2023
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
Via
InvestorPlace
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
November 28, 2023
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reproxalap, an investigational drug
Via
Benzinga
Exposures
Product Safety
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
November 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
What's Going On With Aldeyra Therapeutics Stock?
November 01, 2023
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares are trading higher Wednesday after the company announced that it entered into an exclusive opti
Via
Benzinga
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks
November 01, 2023
Via
Investor Brand Network
Why Are Stocks Up Today?
November 01, 2023
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
November 01, 2023
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 01, 2023
Via
Benzinga
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
November 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc.
October 17, 2023
San Diego, CA -- (SBWIRE) -- 10/17/2023 -- Certain directors of Aldeyra Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Crude Oil Moves Lower; Consolidated Communications Shares Jump
October 16, 2023
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Monday. The Dow traded up 0.93% to 33,983.22 while the NASDAQ rose 1.31% to 13,582.67. The S&P 500 also rose,...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 16, 2023
Via
Benzinga
Nasdaq Gains 1%; Charles Schwab Earnings Top Views
October 16, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.02% to 34,012.79 while the NASDAQ rose 1% to 13,541.79. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Surges Over 200 Points; Empire State Manufacturing Index Falls In October
October 16, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.72% to 33,913.22 while the NASDAQ rose 0.46% to 13,468.82. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 16, 2023
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 16, 2023
Via
Benzinga
Why Aldeyra Therapeutics (ALDX) Stock Is Getting Obliterated
October 16, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are trading lower by 62% to $2.07 during Monday's pre-market session. The company on Monday morning received feedback from the U.S.
Via
Benzinga
DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 29, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)
September 28, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
September 27, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
September 26, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NASDAQ: ALDX Investor Alert: Deadline on September 29, 2023 in Lawsuit Against Aldeyra Therapeutics, Inc.
September 25, 2023
San Diego, CA -- (SBWIRE) -- 09/25/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 29, 2023 in the lawsuit filed for certain investors of Aldeyra Therapeutics,...
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.